Journal
REVUE DES MALADIES RESPIRATOIRES
Volume 35, Issue 4, Pages 430-440Publisher
MASSON EDITEUR
DOI: 10.1016/j.rmr.2017.12.003
Keywords
Pneumonia; Community-acquired pneumonia; Non-steroidal anti-inflammatory drugs; Pleural empyema; Pleural effusion; latrogenic diseases
Categories
Ask authors/readers for more resources
Introduction. -Outpatient treatment of community-acquired pneumonia (CAP) patients with non-steroidal anti-inflammatory drugs (NSAIDs) is frequent, although this is not based on clinical recommendations and there is no scientific evidence supporting better symptom relief in comparison to acetaminophen. State of the art. -Experimental data suggest that NSAIDs alter the intrinsic functions of neutrophils, limit their locoregional recruitment, alter bacterial clearance and delay the resolution of inflammatory processes during acute bacterial pulmonary challenge. In hospitalized children and adults with CAP, observational data suggest a strong and independent association between the outpatient exposure to NSAIDs and the occurrence of pleuropulmonary complications (pleural empyema, excavation, and abscess). In the only study taking into account possible protopathic bias, the association still persists. Other markers of morbidity have been described, including delay in hospital management, prolonged antibiotic therapy, and higher transfer rate to an intensive care unit. Perspectives. -Data describing the role of self-medication and the biological mechanisms involved are needed. Conclusions. -Intake of NSAIDs during outpatient treatment of CAP is probably the second modifiable factor of morbidity after inadequate antibiotic therapy. In light of existing data in children and adults, health authorities should urgently reassess the risk-benefit ratio of NSAIDS in CAR (C) 2018 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available